The GOG Foundation, Inc. and GOG Partners welcome gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to…
The GOG Foundation, Inc. and GOG Partners welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to…
The GOG Highlight Reel distills practice-changing information disclosed during recent major medical meetings into a two-and-a-half-hour segment. This comprehensive course examines recent clinical…
This program provides an in‑depth review of the evolving treatment landscape in ovarian cancer with a focus on emerging science and practical application in patient care. Participants will explore the…
Molecular residual disease (MRD) tracking via tumor-informed circulating tumor DNA (ctDNA) is redefining the surveillance and management paradigm in gynecologic oncology. This session delivers a…
Despite advances in ovarian cancer treatment, outcomes for patients with platinum‑resistant disease remains poor, with therapeutic decisions becoming increasingly complex as novel biomarkers and…
This interactive 90-minute symposium will explore the evolving treatment landscape in endometrial cancer, focusing on the distinctions between dMMR and pMMR disease. Faculty will provide expert…
This course offers a clinically relevant exploration of evolving treatment strategies in ovarian and endometrial cancers for a global audience. The primary focus of this course will help learners…
This interactive 90-minute symposium will explore the evolving treatment landscape in endometrial cancer, focusing on the distinctions between dMMR and pMMR disease. Faculty will provide expert…
Minimal Residual Disease (MRD) testing using circulating tumor DNA (ctDNA) has emerged as a promising tool for improving the management of gynecologic malignancies, including endometrial, ovarian, and…
